Clinical Trials
40 trialsThe DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study
First Hospital of China Medical University
CISLD-8
Zhejiang University
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study
The First Affiliated Hospital of Zhengzhou University
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
CCGLC-001
Tongji Hospital
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
The First Affiliated Hospital with Nanjing Medical University
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Sun Yat-sen University
DoTH
Sun Yat-sen University
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
Shanghai Zhongshan Hospital
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CCGLC-008
Tongji Hospital
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
Beijing Tsinghua Chang Gung Hospital
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Donafenib for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Fudan University
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
Shanghai Zhongshan Hospital
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
Peking Union Medical College Hospital
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Fudan University
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
Fudan University
Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate
First Affiliated Hospital of Zhejiang University
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd